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Abstract
Background: ASP3026 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that has potent in vitro
activity against crizotinib-resistant ALK-positive tumors. This open-label, multicenter, first-in-human phase I study
(NCT01284192) assessed the safety, pharmacokinetic profile, and antitumor activity of ASP3026.
Methods: Advanced solid tumor patients received oral ASP3026 in 3 + 3 dose-escalation cohorts at doses of 25–
800 mg once daily in 28-day cycles. The endpoints were to identify the maximum tolerated dose (MTD), the
recommended phase II dose (RP2D), and the pharmacokinetic profile of ASP3026. A phase Ib expansion cohort
enrolled patients with metastatic, crizotinib-resistant ALK-positive solid tumors at the RP2D, and response was
evaluated by RECIST 1.1.
Results: The dose-escalation cohort enrolled 33 patients, including three crizotinib-resistant, ALK-positive patients,
and the dose-expansion cohort enrolled another 13 crizotinib-resistant, ALK-positive non-small cell lung cancer
(NSCLC) patients. ASP3026 demonstrated both linear pharmacokinetics and dose-proportional exposure for area
under the plasma concentration–time curve and maximum concentration observed with a median terminal half-life
of 35 h, supporting the daily dosing. Grade 3 rash and elevated transaminase concentrations were dose-limiting
toxicities observed at 800 mg; hence, 525 mg daily was the MTD and RP2D. The most common treatment-related
adverse events were nausea (38 %), fatigue (35 %), and vomiting (35 %). Among the 16 patients with crizotinib-
resistant ALK-positive tumors (15 NSCLC, 1 neuroblastoma), eight patients achieved partial response (overall
response rate 50 %; 95 % confidence interval 25–75 %) and seven patients (44 %) achieved stable disease.
Conclusions: ASP3026 was well tolerated and had therapeutic activity in patients with crizotinib-resistant ALK-
positive advanced tumors.
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Background
In recent years, aberrant expression of anaplastic lymph-
oma kinase (ALK) tyrosine kinase receptor has emerged
as a relevant biomarker and therapeutic target for a
number of solid tumors [1, 2]. Different types of alter-
ations in the ALK gene have been implicated in human
cancer tumorigenesis, and different tumor types have
different structural alterations in the ALK gene [3, 4]. In
non-small cell lung cancer (NSCLC), echinoderm
microtubule-associated protein-like 4 (EML-4) and kine-
sin family member 5B (KIF5B) account for the majority
of ALK gene rearrangement lung cancer [5]. The pres-
ence of ALK gene rearrangement defines ~3–13 % of
NSCLC [6–10] that are highly sensitive to the first-
generation ALK tyrosine kinase inhibitor (TKI), crizo-
tinib. Crizotinib (250 mg twice daily) has high efficacy in
patients with NSCLC harboring this oncogenic kinase,
with overall response rates of >50 % [11–13]. Crizotinib
has been established as the standard first-line treatment
for patients with advanced ALK-positive NSCLC [13].
The current National Comprehensive Cancer Network
(NCCN) guideline recommend crizotinib use in patients
with advanced NSCLC harboring ALK gene rearrange-
ment [14]. However, almost all patients develop resist-
ance, typically within 10 months [11, 13, 15, 16].
The most common molecular mechanisms of resist-
ance include amplification of the ALK fusion gene, de-
velopment of resistance mutations, and activation of
alternative or bypass signaling pathways or progression
in the CNS [17]. One strategy to overcome crizotinib re-
sistance is to develop potent small molecule TKIs for
ALK-rearranged genes and/or specifically target the
common resistant mutations, such as gatekeeper muta-
tion L1196M [17].
ASP3026 is a selective, ATP-competitive, second-
generation ALK TKI that was identified through a medi-
cinal chemistry campaign designed to obtain compounds
with a better pharmacologic profile compared with cri-
zotinib. The kinase selectivity of ASP3026 was evaluated
and compared with that of crizotinib against a panel of
86 tyrosine kinases [18]. ASP3026 at 1 μmol/L inhibited
11 tyrosine kinases by more than 50 %, with the highest
selectivity for ALK, ROS1, and ACK kinases, showing
that the kinase selectivity of ASP3026 differed from cri-
zotinib. ASP3026 was more selective for FRK, YES,
ACK, TNK1, and EGFR (L858R), whereas crizotinib had
higher selectivity for MET, RON, LCK, JAK2, MUSK,
TRKs, TYRO3, AXL, MER, and EPHs [18]. ASP3026 fits
within the ATP-binding pocket of both wild-type and
L1196M ALK kinase domains and inhibits their kinase
activities with IC50 values of 10 and 32 nmol/L, respect-
ively. By contrast, crizotinib fits within the ATP-binding
pocket of wild-type ALK kinase domain but not the
L1196M ALK kinase domain. Thus, crizotinib displays
tenfold weaker activity for the mutated EML4-ALK com-
pared with the wild-type ALK gene [18]. In mice bearing
subcutaneous and intracranial xenograft tumors, ASP3026
has potent antitumor activity against both wild-type ALK
and EML4-ALK L1196M xenograft tumors compared with
crizotinib [18]. ASP3026 also has a higher tissue-to-
plasma ratio compared with crizotinib, which could trans-
late into a wide therapeutic margin between efficacious
and toxic doses [18]. Preclinical data indicated that
ASP3026 may have potential therapeutic effects for pa-
tients with crizotinib-resistant ALK-positive NSCLC and
potentially for patients with other cancer types of ALK-
driven tumors.
We conducted this phase I dose-escalation trial to
evaluate the safety and pharmacokinetics (PKs) of
ASP3026 as an oral single agent in patients with ad-
vanced solid malignancies. A planned phase Ib dose-
expansion cohort at the recommended phase II dose
(RP2D) was conducted to evaluate the tumor response
of ASP3026 in patients with metastatic ALK-positive
NSCLC who progressed on crizotinib.
Methods
Clinical study summary
The clinical trial design was a phase I, multicenter,
open-label, dose-escalation and dose-expansion study
(NCT01284192) of ASP3026 in patients with advanced
malignancies. The study was conducted in accordance
with all applicable regulatory requirements and had in-
stitutional review board approval prior to study initiation
at participating institutions. Written informed consent
was obtained from all patients prior to the initiation of
any study-specific procedures.
Patient population
Adult patients (≥18 years of age) with histologically or
cytologically confirmed diagnosis of relapsed/refractory
tumor were included in the dose-escalation study.
Patients had to have Eastern Cooperative Oncology
Group (ECOG) performance status ≤2, adequate life ex-
pectancy >12 weeks, be non-child bearing (or be using
protocol-specified contraceptive measures), and be able
to swallow oral medications. Additional criteria for pa-
tients with ALK abnormalities in the dose-escalation
phase included patients to be positive for ALK abnor-
malities (by any molecular method including, but not
limited to, polymerase chain reaction, direct sequen-
cing, in situ hybridization, or be previously confirmed
by fluorescence in situ hybridization), to not have symp-
tomatic brain metastases, to not to be taking >5 mg pred-
nisone daily, or to not require hepatic enzyme-inducing
anti-seizure medication.
Inclusion into the dose-expansion cohort required pa-
tients to have ALK-positive tumors that had progressed
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on crizotinib. Key exclusion criteria for the dose-
escalation cohort included patients with leptomeningeal
involvement (as assessed through medical history review
or through physical examination), inadequate bone mar-
row, renal and/or hepatic function, and a known history
of long QT syndrome. Brain magnetic resonance im-
aging (MRI) was carried out for all dose-expansion pa-
tients and for all dose-escalation patients known to have
brain metastases at screening. For patients with baseline
brain metastases, MRI was performed at the end of cycle
2 and then every 2 cycles thereafter. Only ALK-positive
subjects were eligible for the dose-expansion cohort;
ROS1 was not included.
Study design and treatments
The study was divided into two parts: dose escalation
and dose expansion. Dose escalation used a traditional
3 + 3 dose-escalation design. Cycles of treatment were
every 28 days with continuous dosing of ASP3026. Pa-
tients were followed-up for safety assessments 30 days
(±7 days) after the last ASP3026 dose. The starting dose
for ASP3026 was 25 mg administered orally once daily.
Dose escalation proceeded to the next seven cohorts of
50, 75, 125, 200, 325, 525, and 800 mg. The first patient
in each dose-escalation cohort was evaluated for dose-
limiting toxicities (DLTs) in cycle 1, day 4. If no DLTs
were reported by the investigator, the remaining pa-
tients in the cohort were enrolled. Therapeutic concen-
trations were projected to be reached above 325 mg.
The protocol allowed that and subsequent doses to be
expanded to enroll an additional three patients who
were known to have tumors tested positive for ALK ab-
normalities once safety was established in the first three
subjects for that cohort. To further address the antitu-
mor effects and the safety of ASP3026 in patients who
progressed on crizotinib, the dose-expansion part of the
study focused on crizotinib-refractory ALK-positive
NSCLC patients.
The primary objectives of the study were to determine
the safety and tolerability of ASP3026 in patients with
advanced malignancies and to determine the maximum
tolerated dose (MTD) and RP2D for ASP3026. The
MTD was defined as the highest dose of ASP3026 at
which <33 % of patients experienced a DLT during cycle
1. Secondary objectives were to determine the PKs and
antitumor activity of ASP3026.
Safety/tolerability assessments
The safety and tolerability of ASP3026 were assessed by
adverse events (AEs) (graded based on NCI-CTCAE
v4.03), laboratory tests, vital signs, electrocardiograms,
and clinical observations.
Dose-limiting toxicity criteria were grade 4 neutro-
penia lasting ≥7 days, febrile neutropenia, grade 3
thrombocytopenia, grade 3 non-hematologic toxicity, ex-
cept for nausea/vomiting or diarrhea (nausea/vomiting
or diarrhea was considered a DLT in patients who had
grade 3 toxicity for ≥3 days or grade 4 toxicity of any
duration), and any study drug-related toxicity resulting
in treatment delay >2 weeks or discontinuation of treat-
ment at the assigned dose level.
Pharmacokinetic assessments
Plasma PKs samples were taken on days 1, 2, 8, 15, 22,
and 28 (±2 days) of cycle 1. On day 1, the following PK
parameters were assessed for ASP3026: area under the
plasma concentration–time curve (AUC24), AUClast,
maximum concentration observed (Cmax), and time of
maximum concentration observed (tmax). On day 28,
AUCtau, Cmax, Ctrough, tmax, CL/F, Vz/F, and t½, calculated
based on the ratio of accumulation for AUC (day 28
AUCtau/day 1 AUC24) (Rac [AUC]), were assessed. Cu-
mulative effects on steady-state ASP3026 plasma levels
were assessed by comparing Ctrough on day 28 divided by
Ctrough on days 8, 15, and 22.
Antitumor assessments
Solid tumor assessment was based on Response Evalu-
ation Criteria in Solid Tumors (RECIST) v1.1. For target
lesions, complete response (CR) was defined as dis-
appearance of all target lesions and pathologic lymph
nodes with a reduction in short axis to <10 mm. Partial
response (PR) was defined as a ≥30 % decrease in the
sum of diameters of the target lesions, taking as refer-
ence the baseline sum of diameters. Progressive disease
(PD) was defined as a ≥20 % increase in the sum of di-
ameters from the smallest sum on the study and the
sum of diameters to be ≥5 mm from the smallest sum
on study. Stable disease (SD) was defined as neither PR
nor PD.
For patients in the dose-expansion cohort with evalu-
able tumor diameter, the best tumor reduction was cal-
culated as the decrease from baseline in the sum of the
target lesions.
Statistical analyses
For continuous variables, descriptive statistics included
the number of patients, mean (standard deviation), me-
dian, and range. For antitumor assessments, the number
and percentage (95 % CI) of patients with CR, PR, SD,
and PD were summarized. The overall best tumor re-
sponse was also summarized. For the objective response
rates, the exact confidence interval of response was cal-
culated only for the dose-expansion cohort using the
Clopper–Pearson method. For continuous PK parame-
ters, the coefficient of variation was calculated. For Cmax
and AUC, geometric mean was calculated. All data pro-
cessing and analyses were performed using SAS® Version
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9.1.3 or higher. The safety analysis set was defined as pa-
tients who received at least one ASP3026 dose. The PK
analysis set was defined as patients who received at least
one dose of ASP3026 and provided the values of drug
concentrations for at least one time point.
Results
Baseline patient characteristics
Enrollment began on 11 January 2011 and closed on 28
June 2013. The data cut-off date was 19 February 2014.
Forty-six patients (33 patients in the dose-escalation co-
hort; 13 in the dose-expansion cohort) were included in
the current analyses.
Table 1 summarizes patients’ demographics. For all
study patients, 22 (48 %) were men and the median
(range) age was 61 (19–77) years. In the dose-escalation
cohort, the most common primary tumor types were
breast and lung adenocarcinoma (both n = 4), leiomyo-
sarcoma and adenocarcinoma (unspecified primary)
(both n = 3), and bile duct, colon, and ovarian cancer
(each n = 2). The median (range) duration of prior
chemotherapy/targeted therapy was 46 (1–171) days. Pa-
tients were not mandatorily screened for brain metasta-
ses at baseline in the dose-escalation cohort.
In the 16 ALK-positive patients (including three ALK-
positive patients from the dose-escalation cohort and 13
from the dose-expansion cohort), 15 NSCLC patients
had ALK rearrangement and one neuroblastoma patient
had an oncogenic ALK gene mutation F1174L [19–21].
Eight patients (50 %) were male, and the median (range)
Table 1 Patient demographics and baseline disease characteristics
Parameter/statistics Dose-escalation cohort Dose-expansion cohort (ALK-positive) Both cohorts
Total (n = 30)a 525 mg (n = 16)b All patients (n = 46)
Sex, n (%)
Male 14 (47) 8 (50) 22 (48)
Female 16 (53) 8 (50) 24 (52)
Race, n (%)
White 25 (83) 1 (6) 26 (57)
Black or African American 5 (17) 14 (88) 19 (41)
Asian 0 1 (6) 1 (2)
Age (years)
Mean (standard deviation) 61.6 (9.6) 51.1 (11.8) 57.9 (11.5)
Median (range) 64 (44–77) 51 (19–71) 61 (19–77)
Weight (kg), mean (standard deviation) 80.3 (20.4) 75.0 (11.6) 78.5 (17.9)
ECOG performance status, n (%)
Grade 0 6 (20) 9 (56) 15 (33)
Grade 1 19 (63) 7 (44) 26 (57)
Grade 2 5 (17) 0 5 (11)
Primary tumor type, n (%)
Lung adenocarcinoma 4 (13) 7 (44) 11 (24)
NSCLC 0 6 (38) 6 (13)
Malignant lung neoplasm 0 2 (13) 2 (4)
Breast 4 (13) 0 4 (9)
Adenocarcinoma (unspecified primary) 3 (10) 0 3 (7)
Leiomyosarcoma 3 (10) 0 3 (7)
Colon 2 (7) 0 2 (4)
Bile duct 2 (7) 0 2 (4)
Ovarian 2 (7) 0 2 (4)
Other 10 (33) 1 (6) 11 (24)
Brain metastases history, n (%) – 9 (56) –
Prior radiation therapy, n (%) 18 (60) 14 (88) 32 (70)
ALK anaplastic lymphoma kinase, ECOG Eastern Cooperative Oncology Group, NSCLC non-small cell lung carcinoma, UNK unknown
aExcludes 3 ALK-positive patients
bIncludes 3 ALK-positive patients from the dose-escalation cohort
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age of the patients was 51 (19–71) years (Table 1); nine
patients (56 %) had brain metastases. All ALK-positive
patients had progressed on crizotinib.
Discontinuations, dose-escalation, and dose-limiting
toxicities
All 30 enrolled patients (excluding three ALK-positive
patients) discontinued treatment in the dose-escalation
cohort (28 due to PD and two for other reasons [see
“Safety/tolerability assessments” section]). At the time of
data cut-off, 12 (75 %) discontinued treatment, 11 due to
PD and one patient died in the dose-expansion cohort.
In the dose-escalation cohort, two patients receiving
800 mg ASP3026 experienced protocol-defined DLTs,
probably related to the study drug, of increased aspartate
aminotransferase and drug eruption (maculopapular rash
on trunk, lower extremities, face, arm, and back), both
grade 3. MTD was determined to be 525 mg, which was
subsequently administered in the dose-expansion cohort.
Adverse events
Within the dose-escalation and dose-expansion cohorts,
29 patients (97 %) and 16 patients (100 %) experienced ≥1
AE, respectively. Drug-related AEs were reported by 20
patients (67 %) in the dose-escalation cohort and 15 pa-
tients (94 %) in the dose-expansion cohort (Table 2).
Serious AEs (SAE) were reported by seven patients
(23 %) in the dose-escalation cohort; one SAE was pos-
sibly related to the study drug (international normalized
ratio [INR] increased that resolved after drug withdrawal).
Serious AEs were reported by five patients (31 %) in the
dose-expansion cohort; one SAE was possibly related to
the study drug (abnormal liver function test that did
not resolve after drug withdrawal) and another prob-
ably related to the study drug (keratoacanthoma that
resolved after drug withdrawal). There were three
deaths on study, all of which were due to PD and not
related to the study drug.
Adverse events leading to drug discontinuation oc-
curred in two patients in the dose-escalation cohort (one
patient experienced a pulmonary embolism [not study
drug-related] and an increased INR [possibly study drug-
related]); one patient experienced increased aspartate ami-
notransferase that was probably related to the study drug.
AEs leading to drug discontinuation occurred in one pa-
tient in the dose-expansion cohort (an abnormal liver
function test [possibly study drug-related] and bilateral
pleural effusion, constrictive pericarditis, and disease pro-
gression [all not study drug-related]).
Laboratory parameters and electrocardiograms
There were no meaningful changes in any clinical la-
boratory parameters or vital signs over time or any over-
all shifts from baseline in hematology or laboratory tests.
There was an increase in QTcF values in some patients.
Mean (standard deviation) maximal increase of 47.0 (10.7)
ms was reported at the 325-mg dose; at the MTD
(525 mg), the mean (standard deviation) maximal increase
was 25.8 (16.8) ms in the dose-expansion cohort.
Table 2 Summary of AEs possibly or probably related to study drug occurring in ≥2 patients in either cohort
Dose-escalation cohort Dose-expansion cohort (ALK-positive) Both cohorts
Total (n = 30)a 525 mg (n = 16)b Total (n = 46)
Overall 20 (67) 15 (94) 35 (76)
Nausea 7 (23) 10 (63) 17 (37)
Vomiting 6 (20) 10 (63) 16 (35)
Fatigue 13 (43) 3 (19) 16 (35)
Decreased appetite 1 (3) 4 (25) 5 (11)
Diarrhea 3 (10) 2 (13) 5 (11)
Rash 0 3 (19) 3 (7)
Headache 1 (33) 2 (13) 3 (7)
Constipation 2 (7) 1 (6) 3 (7)
Peripheral neuropathy 0 2 (13) 2 (4)
Cataract nuclear 0 2 (13) 2 (4)
Periorbital edema 0 2 (13) 2 (4)
Blurred vision 0 2 (13) 2 (4)
Anemia 2 (7) 0 2 (4)
Increased blood creatinine 2 (7) 0 2 (4)
ALK anaplastic lymphoma kinase
aExcludes 3 ALK-positive patients
bIncludes 3 ALK-positive patients from the dose-escalation cohort
Li et al. Journal of Hematology & Oncology  (2016) 9:23 Page 5 of 9
ASP3026 pharmacokinetics
Mean ASP3026 plasma concentrations by dose are
shown in Fig. 1, and PK parameters are provided in
Tables 3 and 4. ASP3026 had rapid oral absorption,
with a tmax of approximately 3 h. The mean (standard
deviation) accumulation half-life was 25 (37) h (me-
dian half-life, 35 h (range, 22–85 h). Steady-state
plasma concentrations were reached by day 8 for both
the dose-escalation and dose-expansion cohorts. After
multiple dosing (day 28), ASP3026 showed both linear
and dose-proportional exposure (Cmax and AUClast)
over the 25- to 800-mg dose range; slope estimates
(95 % CI of slope) comparing dose-normalized expos-
ure to dose were 0.170 (−0.018, 0.358) and 0.090
(−0.097, 0.277) for Cmax and AUClast, respectively.
ASP3026 antitumor effects
In the dose-expansion cohort (crizotinib-resistant ALK-
positive; 15 NSCLC; one neuroblastoma), the best over-
all response was PR in eight patients (50 %) and SD in
seven patients (44 %) (Table 5). The objective response
rate (CR + PR) was 50 % (95 % CI, 25–75 %). Of the
eight patients experiencing a PR, six had lung target tu-
mors. The other two patients had the following target
tumors: patient 1 had liver and adrenal tumors; patient 2
had pancreas tail, soft tissue peritoneum, paraaortic, and
uterine tumors.
For patients in the dose-expansion cohort with evalu-
able tumor diameter, the best tumor reduction is shown
in Fig. 2, along with the duration of response that ranged
from 27 to 338 days. For those patients with brain
Fig. 1 Mean plasma concentration of ASP3026, cycle 1, day 1. a Semi-log plot. b Linear plot. For patient numbers at each dose, refer to Tables 3
and 4
Table 3 Pharmacokinetic parameters for ASP3026 (cycle 1, day 1)
Dose (mg; once daily) Number Cmax (ng/mL) tmax (h)
a AUC24 (ng h/mL)
Dose-escalation cohort
25 4 32.0 (10.2) 3.0 (0.5–4.0) 378 (104)
50 3 99.7 (56.6) 3.0 (2.0–4.0) 846 (225)
75 3 87.6 (40.3) 8.2 (2.0–24.2) 1155 (442)
125 4 261.7 (131.1) 5.0 (1.0–8.0) 3000 (860)
200 4 490.5 (68.6) 2.5 (2.0–3.0) 4585 (1310)
325 3 586.2 (109.7) 3.0 (3.0–8.0) 7950 (1957)
525 6 1750 (1279) 4.0 (3.0–4.2) 18,543 (10,812)
800 3 1633 (252.7) 3.0 (2.0–8.0) 21,796 (5990)
Dose-expansion cohort
525 16 961.0 (563.8) 3.1 (2.0–8.0) 11,746 (9063)
Calculated accumulation ratio (AUCd28, tau/AUC24h of cycle 1, day 1)
AUC area under the concentration–time curve, Cmax maximum concentration observed, NA not applicable, tmax time of maximum concentration observed
aMedian (range); mean (standard deviation) for other parameters
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metastasis detected at study entry, brain MRI was per-
formed at the end of cycle 2 and then every 2 cycles there-
after per protocol. Progressive or new brain metastasis
was considered as PD in addition to RECIST evaluation
for extracranial disease. The median progression-free sur-
vival in ALK-positive patients was 6 (95 % CI, 4–9)
months.
Discussion
Gain-of-function ALK gene alterations have been de-
tected in several types of solid tumors, B cell lymphomas
and pediatric tumors [2, 3, 22], for which crizotinib has
either established or promising clinical efficacy [17]. Sev-
eral second- and third-generation ALK inhibitors have
also shown either established or promising clinical activ-
ity for ALK-positive NSCLC patients who progressed on
crizotinib, supporting the development of potent ALK
inhibitors as an effective strategy to overcome resistance
to crizotinib [17].
We conducted this first-in-human trial to determine
the safety, pharmacokinetic, and antitumor effects of a
novel second-generation ALK inhibitor ASP3026. Over-
all, ASP3026 was well tolerated with no treatment-
related deaths. The AE profile in the dose-expansion
cohort was similar to that reported for crizotinib [11],
with gastrointestinal complaints (nausea and vomiting)
being some of the most frequently reported. The con-
stellation of AEs in this small sample set was also simi-
lar to other agents in this class, such as ceritinib and
alectinib, with gastrointestinal AEs commonly reported
[16, 23, 24].
ASP3026 had linear PK parameters and demon-
strated dose proportionality over the dose range of
25–800 mg once daily. ASP3026 had good oral ab-
sorption, with a tmax of approximately 3 h; median
half-life was 35 h (range, 22–85 h), confirming that
once-daily dosing was suitable.
Of the 16 crizotinib-resistant ALK+ subjects (15
NSCLC and one neuroblastoma) who received 525 mg
ASP3026, eight (50 %) achieved PR and seven (44 %)
achieved SD at 8 weeks. When restricted to ALK-positive
NSCLC patients, the PR and SD rates were 8/15 (53 %)
and 6/15 (40 %), respectively. Although caution is war-
ranted due to a lack of head-to-head comparison, this
tumor response rate is comparable with those observed
in other second-generation ALK inhibitors, such as ceri-
tinib and alectinib, in crizotinib-resistant NSCLC pa-
tients [16, 24].
Our study has several other limitations. First, although
our study was designed to allow the enrollment of pa-
tients with ALK-driven advanced tumors other than
NSCLC, only one patient with advanced neuroblastoma,
who had a commonly detected ALK F1174L mutation
Table 4 Pharmacokinetic parameters for ASP3026 (cycle 1, day 28)
Dose (mg; once daily) Number Cmax (ng/mL) tmax (h)
a AUC24 (ng h/mL) t½ (h)
Dose-escalation cohort
25 3 68.4 (42.3) 3.0 (1.0–8.1) 1038 (335) 36.6 (15.7)
50 3 143 (62.4) 3.0 (2.0–4.0) 2111 (541) 35.2 (18.7)
75 3 352.5 (147.5) 3.0 (2.0–4.0) 5627 (1791) 84.7 (53.9)
125 1 667.9 (NA) 2.1 (NA) 8967 (NA) 36.7 (NA)
200 3 681.8 (104.8) 3.0 (2.1–3.0) 7620 (1699) 21.9 (1.4)
325 3 1159 (856.9) 4.0 (3.0–4.0) 18,764 (17,647) 26.3 (29.1)
525 6 2819 (1681) 3.5 (2.0–4.1) 40,114 (24,479) 27.3 (5.0)
800 1 4854 (NA) 4.0 (NA) 78,081 (NA) 37.9 (NA)
Dose-expansion cohort
525 15 1331 (813.7) 4.0 (0–4.1) 19,993 (10,552) 24.9 (12.7)
Calculated accumulation ratio (AUCd28, tau/AUC24h of cycle 1, day 1)
AUC area under the concentration–time curve, Cmax maximum concentration observed, NA not applicable, tmax time of maximum concentration observed
aMedian (range); mean (standard deviation) for other parameters
Table 5 Best overall response to ASP3026 in the dose-
expansion cohort
Parameter Expansion cohort ASP3026
525 mg (n = 16)
Best overall responsea, n (%)
Complete response 0
Partial response 8 (50)
Stable disease 7 (44)
Progressive disease 0
Unable to evaluate 1 (6)
Objective response (complete
response + partial response)
n (%) 8 (50)
95 % CIb 25–75 %
CI confidence interval
aBased on RECIST guidelines (v1.1) and International Working Group revised
response criteria
bExact CI obtained using Clopper–Pearson method
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[19–21] and who progressed on prior crizotinib, was
identified during the enrollment period. This is because
routine molecular testing for other types of tumors did
not, and has not, become standard clinical practice. Sec-
ondly, multiplexed genomic testing, such as a targeted
resistance mutation panel of the ALK kinase domain
and targeted next-generation sequencing, was not re-
quired at study entry for determining molecular mecha-
nisms of resistance at disease progression to crizotinib.
This is unlikely to affect our result. Although different
resistance mutations may confer variable responses to
subsequent ALK inhibitor therapy [15, 17, 25], most
second-generation ALK inhibitors, such as ceritinib and
alectinib, as well as ASP3026, have strong efficacy
against both secondary mutations in the ALK tyrosine
kinase domain and wild-type ALK gene amplification
[16, 24]. Nevertheless, with the increasing use of clin-
ical molecular profiling tests at treatment resistance in
patients with advanced malignancies, individualized
treatment beyond a second-generation ALK inhibitor
should be based on the assessment of molecular mech-
anism of resistance.
Conclusions
The second-generation ALK inhibitor, ASP3026, showed
clinical activity in patients with ALK-positive solid tu-
mors, especially NSCLC, with half of the patients achiev-
ing partial response and a favorable safety profile with a
MTD and R2PD of 525 mg daily.
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AE: adverse event; ALK: anaplastic lymphoma kinase; AUC: area under the
concentration–time curve; Cmax: maximum concentration; CR: complete
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PKs: pharmacokinetics; PR: partial response; RP2D: recommended phase 2
dose; SD: stable disease; TKI: tyrosine kinase inhibitor; tmax: time to maximum
concentration.
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